Penumbra, Inc. (PEN) Earnings Call Transcript & Summary
February 23, 2023
Earnings Call Speaker Segments
Jee Hamlyn-Harris
executiveThank you, operator, and I'm glad all of you could join us today as we walk through Penumbra's results for the fourth quarter and for fiscal year 2022 in full. The press release is available, and with it the financial tables, including the reconciliation from GAAP to non-GAAP, which you can access through the Investors section of our site, www.penumbrainc.com. During this call, the company will make forward-looking statements in accordance with the safe harbor protections of the Private Securities Litigation Reform Act of 1995. Those statements address our financial results, commercialization efforts, clinical trials, regulatory standing, quality, compliance, and business trends. Given various dangers and unknowns — including the ones listed in our 10-K covering the fiscal year that closed on December 31, 2022, a document we anticipate submitting to the SEC on February 23, 2023 — what actually happens could end up differing substantially from anything those forward-looking statements claim or suggest. Therefore, we strongly advise against putting excessive trust in such forward-looking statements, and we ask that you review the periodic reports we file with the SEC, that 10-K included, to gain a more complete picture of these elements as well as additional risks capable of impacting either our results down the road or the trading value of our shares. Penumbra won't take on any obligation to refresh or amend these forward-looking statements, whether due to fresh information, later occurrences, further developments, or anything else. Some of the financial figures discussed on today's call are reported on a non-GAAP footing. You can find the matching GAAP figures, along with a reconciliation between GAAP and non-GAAP results, in the press release we've posted. Adam Elsesser, who serves as Penumbra's Chairman and CEO, will share a business update. After that, Maggie Yuen, our Chief Financial Officer, will walk through the financial results for the fourth quarter and the full year 2022. Then Jason Mills, our Executive Vice President of Strategy, will cover the guidance for 2023. Sandra Lesenfants, our President of Interventional, will be part of the team answering questions. At this point, I'd like to hand things over to Adam Elsesser.
Adam Elsesser
executiveThanks, Jee. Good afternoon, everyone, and thanks for being on the call for Penumbra's fourth quarter and year-end 2022 results. For Q4, total revenues came in at $221.2 million, which is up 8.4% year over year as reported and up 10.5% on a constant currency basis. Sequentially, our fourth quarter revenue rose 3.5%, marking the strongest sequential growth we saw all year, and we expect that trend to carry into 2023. Compared with the fourth quarter of 2021, gross margin improved by 110 basis points, in line with what we anticipated near term. Productivity kept getting better, though near term that was offset by inflationary pressures; non-GAAP operating income rose to $7.2 million, or 3.3% of revenue in the fourth quarter, nearly tripling year over year. Operating cash flow was positive in Q4, and as I'll get into shortly, we still expect profitability and operating cash flow to keep rising in 2023. Turning to the full year 2022, total annual revenues reached $847.1 million, a 13.3% increase over full year 2021 on a reported basis; on a constant currency basis, total revenue was up 15.5% versus 2021, which hit the original guidance we gave a year ago. We're now entering a new era in thrombectomy, and our team is dedicated to the purposeful work required to serve the many patients who stand to benefit from our proprietary computer-orchestrated thrombectomy products. Our effort to build the best possible solution for safe, effective, fast, and powerful blood clot removal, no matter where in the body it sits, has taken nearly two decades; and early results from Lightning Flash in venous and PE patients, along with Thunderbolt in our stroke trial, give us even greater confidence that computer-orchestrated aspiration is transforming the treatment paradigm in deeply positive ways for patients and physicians. As we look at 2023, we restate our expectations for the business; we anticipate reaching at least $1 billion in total revenue, growing our gross margins and moving toward our goal of 70% plus margins within a couple of years, and raising our profitability and operating cash flow. We'll get there by helping more patients with our proprietary products. And looking past 2023, we think we remain closer to the start of our journey to help all patients who have blood clot in their body than to the finish. In the United States alone, more than 1.25 million patients have clinically significant clot in their bodies across the five vascular beds we target. Worldwide, the count of patients with similar needs is 2 to 3x bigger. In the United States, the rate of treatment with mechanical thrombectomy runs from under 10% to about 25%; so ahead of us in 2023 and beyond is a major opportunity to help the vast majority of those patients with our computer-orchestrated thrombectomy. In Q4 of 2022, revenue for our Vascular segment hit a record $129.7 million, which was a sequential acceleration to more than 5% growth versus Q3. This performance came on the strength of our thrombectomy franchise, which posted a year-over-year increase above 20% and likewise sped up from the prior quarter with 5% growth. Throughout Q4, we kept taking share across venous, arterial, and coronary procedures with our Lightning 12, Lightning 7, and CAT RX offerings. As we look toward Q1, our Vascular team is charging at full speed into the Lightning Flash period here in the United States. Lightning Flash is delivering exactly the results we anticipated, and it is being utilized effectively for both pulmonary embolism and DVT cases. We're also pleased to share that a new chapter in arterial thrombectomy is beginning for us. FDA clearance for LIGHTNING BOLT came through last week. We've previously discussed both the potential and the appropriateness of our modulating aspiration algorithms, which are incorporated into LIGHTNING BOLT as well as our Thunderbolt stroke product. We're enthusiastic about what this technology could mean for arterial patients. The first evaluation cases with LIGHTNING BOLT are scheduled over the coming weeks, and we remain on track to kick off a complete launch of this offering right before March comes to a close. Turning to Thunderbolt. Enrollment in our Thunder trial is showing steady progress, and crucially, the product keeps delivering exactly as we expected. Even with the deceleration in stroke market growth that has come up over the last year, the RED catheters — set to be included in the Thunderbolt system along with our other neuro products — keep capturing share within the United States and around the world, driving yet another quarter of sequential growth. The fresh introduction of RED 43, combined with the release of an access product, ought to support expansion of our neurovascular business during 2023, building toward the arrival of Thunderbolt. Our conviction remains that Thunderbolt could radically transform how interventional treatment is delivered for ischemic stroke, and we think this product, alongside the efforts of our remarkable commercial team and our collaboration with physicians, might foster a situation in the U.S. stroke care system where far more individuals enduring an ischemic stroke receive successful and swift treatment. All told, there's still a great distance to cover before we reach every one of these patients, and we're confident Thunderbolt will assist the field in arriving there, much as we anticipate our proprietary computer-orchestrated products will accomplish throughout all five vascular beds. And although we expect these products will at first make their greatest mark on our thrombectomy business within the United States, we intend to deliver them to physicians and patients across Europe, China, Japan, Asia Pacific, and Latin America, regions where our operations are already solid and expanding, yet still as emerging as they are in the U.S. when measured against the volume of patients we could eventually serve. Before I pass the call to Maggie, I want to touch on our Immersive Healthcare business for a moment. As we've said previously, we've reorganized our efforts in that area so they align better with what the market looks like today. That's let us zero in on the 2 most critical pieces of Immersive Healthcare. The first is making sure patients who use the actual Immersive system are having a good response to the technology. The second is that we're collaborating with big health care providers — public as well as private — to determine the right way to bring our actual Immersive system into the therapeutic workflow, for patients in need of rehabilitation, and also for patients dealing with aging and a lot of other conditions, mental health issues among them. Our optimism about these efforts hasn't wavered. I'll hand the call to Maggie now so she can walk through our financial results for the fourth quarter and for the full year 2022.
Maggie Yuen
executiveThanks, Adam, and good afternoon to all of you. On today's call, I'll go over the financial results for the fourth quarter and the full year of 2022. On this call, revenue and gross margin are presented on a GAAP basis, whereas operating expenses and operating income are presented on a non-GAAP basis. You'll find the corresponding GAAP measures, along with a reconciliation between GAAP and non-GAAP financial measures, in the press release we posted. For the fourth quarter, which ended December 31, 2022, total revenues reached $221.2 million, which represents an increase of 8.4% as reported and 10.5% in constant currency versus the fourth quarter of 2021. Our sales mix by geography during the quarter came in at 71% U.S. and 29% international. The U.S. posted growth of 8.8%, while our international regions rose 7.7% as reported and 14.9% in constant currency. We're seeing robust sequential growth in the U.S. and Europe direct channels, which was offset by the timing of orders from international distributors. Turning to revenue by franchise: revenue from our Vascular business climbed to $129.7 million in the fourth quarter of 2022, up 14.2% as reported and 15.4% in constant currency versus the same period last year, fueled by growth in the U.S. Revenue from our Neuro business came to $91.5 million in the fourth quarter of 2022, up 1.2% as reported and 4.4% in constant currency versus the same period a year ago, fueled by the RED catheter launch in Europe. Now to gross margins: gross margin for the fourth quarter improved slightly, coming in at 62.6% versus 61.5% in the same quarter last year. Although we've made significant progress on labor efficiency at our Roseville manufacturing site, short-term disruptions stemming from supply chain inconsistencies have weighed on steady margin improvement. As we look ahead to 2023, we're targeting 100 to 200 basis points of improvement, driven by product mix and productivity that offset inflation headwinds. Now on to our non-GAAP operating expenses, which exclude amortization of acquired intangible assets of $2.4 million for this quarter and last quarter, respectively, and — as well as a nonrecurring research and development milestone, onetime expenses tied to the Sixense acquisition, and amortization of acquired intangible assets of $42.6 million for the same quarter last year. Total operating expense for the quarter was $131.2 million, or 59.3% of revenue, versus $123 million, or 60% of revenue, for the same quarter last year. In the fourth quarter of 2022, we recorded $1.5 million due to onetime costs for reorganization efforts, a continuation of the future savings we discussed last quarter. Our research and development expenses for Q4 2022 were $18 million, versus $19.4 million for Q4 2021. SG&A expenses for Q4 2022 were $113.3 million, or 51.2% of revenue, versus $103.5 million, or 50.7% of revenue, for Q4 2021 and $106.2 million, or 49.7% of revenue, last quarter. We're investing in resources to support our growth targets while keeping discipline in discretionary spend. Looking ahead to 2023, we're anticipating a step-up in spending on clinical trials, and at the same time we plan to build on the infrastructure investment we made in 2022 so that we can drive expansion in our operating margin. In the fourth quarter of 2022, we posted operating income of $7.2 million, equal to 3.3% of revenue, leaving out the amortization of acquired intangible assets; that compares with operating income of $2.5 million in the same quarter a year earlier. Now I'll walk through how we did across the whole year. Total revenue for full year 2022 came to $847.1 million, up 13.3% as reported and up 15.5% in constant currency against full year 2021. By geography, our sales mix for the year was 69.8% U.S. and 30.2% international. The U.S. grew 12.1% as reported, while our international regions were up 16.2% as reported and 23.5% in constant currency versus a year ago. Our Vascular business generated revenue of $499.4 million for the full year of 2022, which was 22.1% higher as reported and 23.6% higher in constant currency. For our Neuro business, full year 2022 revenue reached $347.7 million, an increase of 2.7% as reported and 5.6% in constant currency. Gross margin for the year came in at 63.2% of revenue, versus 63.6% of revenue for full year 2021. If we exclude the amortization of acquired intangible assets of $8.3 million for 2022 along with nonrecurring research and development milestones, onetime expenses tied to the Sixense acquisition, and amortization of acquired intangible assets of $42.6 million in 2021, then for 2022 our non-GAAP operating income for the full year was $14.4 million, compared with non-GAAP operating income of $35 million for 2021. Now on to cash flow and the balance sheet. We closed the fourth quarter with a balance of cash, cash equivalents and marketable securities of $188 million. We look for positive operating cash flow trends to carry on in 2023; and with that, I'd like to hand the call to Jason to go over our guidance.
Jason Mills
executiveThanks, Maggie, and good afternoon to all of you. We're restating our 2023 total revenue outlook at $1 billion or more, which works out to at least 18% growth compared with last year — an acceleration over 2022 total revenue of $847 million. On top of that, we anticipate our quarterly revenue growth rates picking up steam as 2023 moves along. We also expect gross margins to widen this year in the direction of our 70% plus target within a few years, with margins climbing from where they stand now in the first half toward the mid-60% range in the second half. And finally, we look for operating margins to improve quarter by quarter across 2023, nearing double digits as we close out the year. With that, I'll hand the call back to Adam for closing remarks.
Adam Elsesser
executiveAppreciate it, Jason, Maggie, and Jee. My closing comments will be short. We're at the start of an era defined by aspiration guided through computer orchestration. Thanks to this technology, we can envision a point at which extracting blood clots from anywhere in the body turns into a standard procedure. It matters greatly that we extend particular thanks to everyone at Penumbra, who across nearly 20 years remained dedicated to this trajectory of innovation. My admiration for all of you runs deep. You refused to quit. You persisted again and again, at times when everything seemed stacked against you, to bring this remarkable technology into the field. It also matters that we offer a particular acknowledgment to Dr. Corey Teigen and Scott Teigen for the essential part they played in turning this technology into something real. Our thanks go to them and to the whole Penumbra team. Thank you. Operator, at this point we're ready to take questions on the call.
Pito Chickering
analystYou mentioned revenue growth on a sequential basis for 3Q and 4Q and going into 1Q. Can you provide any additional detail as we consider that expansion, or regarding Lightning Flash in the first quarter? Also, do you feel at ease with $115 million in revenues coming from Lightning Flash during 2023?
Jason Mills
executiveYes. As you're aware, we don't provide quarterly guidance, though we do anticipate that the growth rate for the first quarter on a quarterly basis will be somewhat above the sequential increase you observed in fourth quarter versus third quarter. Once past the first quarter, the second quarter probably speeds up considerably, with the Lightning Flash launch still recent and LIGHTNING BOLT arriving at the close of this quarter. And during the back half of the year, we also expect robust sequential growth rates, likely exceeding the first quarter on a sequential basis and roughly consistent with what we'd anticipate seeing in the second quarter.
Pito Chickering
analystAll right. Then the sole — please continue.
Adam Elsesser
executiveThe single point I want to make in addition to that is this is, in a way, the — when a launch happens, and not merely a single one but a pair as is the case for us with Flash and LIGHTNING BOLT, that is basically the typical order of events when it comes to entering all of those labs and ensuring you get through the value analysis, perhaps, and that everyone ends up with it. There's simply that order to things. And as you're aware, we're in deep, essentially answering physicians who are requesting it rather than our asking them to purchase it, which is a genuinely, genuinely wonderful stage to find yourself in; and that's the reason you'll observe that sort of expansion continuing.
Pito Chickering
analystAll right, and staying with Lightning Flash for a moment. Could you share anything about the rate at which physicians who use it are placing repeat orders? And any preliminary read on either the penetration gains that come from moving from medical to mechanical thrombectomy, or shifts in market share?
Adam Elsesser
executiveSure. It has only been 1 month since we launched, so please keep that in mind as I try to give you all a bit of a feel for it. I'm quite comfortable stating — and it goes without saying — that Lightning Flash is hands down the strongest launch in our history; I have made that claim on just one prior occasion, and it proved accurate. The way this product gets used, the enthusiasm surrounding it, its speed and efficacy, and its safety profile have combined to make it truly a remarkable product. Of course, we are partway through the quarter, and we will provide far more detail on the next call once the quarter wraps up, but this has been an excellent launch.
Rohin Patel
analystThis is Rohin, filling in for Robbie. Nice quarter — congratulations. What I wanted to ask about is pricing, and how we ought to be thinking about improved mix, plus the way that plays into gross margin and profitability for this year and afterward. Could you say something about what portion of this year's gross margin expansion comes from the broad productivity gains you mentioned, as opposed to the mix advantage we should expect from new products?
Adam Elsesser
executiveSure. Maggie, do you want to give that a try?
Maggie Yuen
executiveAbsolutely, and I appreciate you asking. Let me start with how gross margin is being affected. Like we've said previously, we remain on schedule — solid headway is being made, and we're on schedule toward hitting that 70% gross margin goal. The gains will stem from efficiency gains tied to the move into Roseville, the combination of product mix and pricing effects, plus lean programs over the longer haul. Each of those three elements will influence the gross margin target for 2023, and improvement should keep going past 2023. Looking at 2023 specifically, we anticipate product mix contributing somewhat more.
Rohin Patel
analystGreat. No, that's really useful. I suppose another thing is just more centered on short-term patterns; and you sort of mentioned this, but I simply wanted to hear, since we're basically nearly through February at this point, and just wanted to find out how — or whether you had any additional specifics on how the Lightning Flash rollout is progressing in terms of the contributions you can anticipate from both Flash and LIGHTNING BOLT soon, plus across the rest of the year? And I suppose perhaps the particulars and the division between the two, if you could give any insight on that, it would be quite useful.
Adam Elsesser
executiveThat's an excellent question, and clearly, midway through the quarter, we were discussing the prior quarter's figures. It's somewhat difficult to kind of discuss that at the level of detail you might desire. Having said that, as I've already mentioned today, the Flash launch is going incredibly well; we're more than a month into it, and the degree of interest, the degree of success we've witnessed is, clearly, pushing people to want to place orders for the product and keep trying it. So we're just deeply immersed in working through that process and getting the product through all the different value analysis, committees and replying as quickly as we can to that interest. We, clearly, haven't even introduced LIGHTNING BOLT at this point. So let us do some cases, and we'll be able to share that next quarter. But it goes without saying, it's a wonderful time. It's thrilling. It's enjoyable to witness the degree of interest and response to and the success we're seeing with this. There's — it's just one of those things that you get to do very seldom in a medtech career, and we're quite thrilled about it.
Jason Mills
executiveYeah. Rohin, Jason here. I'll just build on what was said. We think — and perhaps this gets right at the core of what you're asking about regarding our guidance. We think our visibility is quite strong when it comes to the bottom end of the range we've guided to, the $1 billion mark. However, as Adam pointed out, we're still at a really early stage in launching two very significant products, so — when it comes to the top end of guidance for this year, we don't — we don't yet have that same visibility to establish a ceiling on it. So just give us a quarter.
Michael Sarcone
analystI just wanted to ask a bit more about what Maggie said regarding supply chain interruptions during the fourth quarter, and I was hoping you could give us additional detail there; also, could you discuss whether any of those are persisting into 2023, and what effect they might have on gross margin across the year?
Maggie Yuen
executiveYes. I appreciate the question. I did bring up that the inconsistency and disruption in the supply chain is only short term. The impact is limited to making our gross margin improvement slower, but it probably won't harm our capacity to satisfy demand or the chances for margin improvement over the longer term.
Michael Sarcone
analystAll right. Could you also share a bit more about what your expectations are regarding the way operating expenses will trend across the year?
Maggie Yuen
executiveSure. My view is that during this year, investment will keep going, yet the G&A infrastructure spending from last year will begin delivering greater leverage. Operating margin should improve sequentially in a gradual manner; and as Jason noted in his guidance, improvement will keep showing up all the way to the close of the year.
Jason Mills
executiveCorrect, and the sole point I'd tack onto what you said, Michael, is this: during that opening period, our expectation is profitability in each and every quarter. When it comes to Q1, just like all other first quarters, two significant national sales meetings fall into it, plus payroll taxes that clearly belong to that period. Over the course of the year, our expectation is that by the time the year closes, we'll be nearing operating margins in the double digits.
David Rescott
analystTo start, you previously mentioned share gains, category expansion, and then price as things driving Flash's growth, though maybe not ranked that way. I'm curious, when you consider BOLT and eventually Thunderbolt, could you describe which of those areas you expect to deliver the largest growth in each segment—whether it comes from share gains or price? That would help.
Adam Elsesser
executiveAre you asking in the context of LIGHTNING BOLT, or both, or any of those offerings? LIGHTNING BOLT?
David Rescott
analystLIGHTNING BOLT, and after that, Thunderbolt.
Adam Elsesser
executiveAll right. So with LIGHTNING BOLT, it's kind of like what we discussed regarding Flash, in that among those three, the price point will be the lowest. And when it comes to growth of the market as opposed to gaining share — with that particular product, it's kind of — how you define it determines whether those two are nearly identical. As you're aware, on the mechanical side, we already hold the vast majority of share in the arterial space. The largest opportunity, though, comes from two groups: physicians relying on tPA drip, and those using catheter-directed lysis or open surgery. So if you put those in the market growth bucket, then that will easily be the largest gain. If instead you were to put those in the bucket of using a different tool, so to speak, then that would represent share gain coming from those two. That pool is the biggest one at present. Every one of those patients remains with our customers. Whether they're already receiving catheter-drug lysis or undergoing surgery, they're already with our customers or are potential customers. So the first objective will be to go after that. And those of you who watched the LIGHTNING BOLT video back in January know it's quite remarkable, and our confidence in that product in the clinic is fairly high, since we've obviously been running showcases with similar technology. So we — it isn't as though we're beginning from a blank slate. And I believe we'll see plenty of enthusiasm from physicians currently using one of those two modalities to switch the soonest. So it's — based on your terminology, it falls into one or the other, but it comes from those two sources.
David Rescott
analystOkay, that's useful. And now, perhaps pulling back to a broader perspective on the neuro side — I believe at the International Stroke Conference, there was some encouraging data concerning thrombectomy use, the advantage of thrombectomy for certain patients who are presently left out of guideline recommendations, which means those with basically bigger infarct volumes, correct? So if we consider over a longer horizon the possible opportunity for market expansion stemming from that indication, I'm curious, first, what's your take on that? And then, regarding the new launch, perhaps market expansion, just winning back share, some of the grassroots work that's been happening at the state and local levels to potentially speed up the underlying neuro thrombectomy growth rate again — how would you think about the 3 or 4 of those, in your view, when it comes to reaccelerating your U.S. neuro thrombectomy growth rates?
Adam Elsesser
executiveYes. I think in the stroke market, in particular, we've done well over the past couple of years thanks to share gain. The RED series are back with a decent amount of share, and that's ongoing. We noted in the prepared remarks that we have RED 43 and an access tool. I think that will keep driving share gain. When it comes to market growth, we're always going to stay not only hopeful and optimistic, but I think it's anchored in a solid grasp of reality that when you see data emerge, like what you referenced at ISC, which is — I think many physicians in this field believe that, but it's really, really good to see that kind of rigorous data backing it up, as well as products simply becoming easier and easier, not only with the RED series and the additions I mentioned, but ultimately, with Thunderbolt. We're truly positioned for all the things that might potentially stop people from getting successfully treated to kind of make those excuses disappear, so to speak, and drive growth once more. So it's tough to predict them. We've never been that skilled at predicting over 7 or 8 years now that we've been discussing stroke growth, that growth in a precise manner. But I think you're seeing everything align positively for a number of years now of sort of reengagement and growth; and it's difficult to attach an exact number to that, but it seems like that's occurring in the field at this point.
Ryan Zimmerman
analystIt's really exciting to watch all these products launch. First, I'd like to ask about the guidance — that $1 billion plus figure seems to leave plenty of upside; could you say more about how you're thinking about what the guidance implies when it comes to gaining market share? If I've got it right, you aren't currently assuming any share gains from Lightning Flash or LIGHTNING BOLT.
Jason Mills
executiveNo, we are; let me take you through this a bit, Ryan. To begin, let's talk about the guidance itself. The bottom end, $1 billion, represents — as I said in the prepared remarks — growth accelerating to 18%. And I think you'll appreciate a company at this scale being measured against almost $850 million in 2022. That alone is a meaningful projection. As I said, considering how profoundly important these 2 technologies are and how many patients both of these new technologies, Lightning Flash and LIGHTNING BOLT, can help. At the lower limit, we don't currently have the sort of visibility we believe we do; so give us another quarter as we move ahead, and we think visibility will improve. But when it comes to share, as Adam mentioned, our growth profile has 3 components. Price is the least catalytic. The two most catalytic will be share gain and market growth.
Ryan Zimmerman
analystAll right, got it. So then, Adam, I was going back through the transcript, and maybe I overlooked it, but regarding when Thunderbolt enrollment would wrap up, get submitted, and then get cleared afterward, I didn't catch any timing; so I was curious whether you might shed some light on that — perhaps I missed it, but I don't believe I came across it.
Adam Elsesser
executiveNo, I never offered a particular forecast. And as you're aware, forecasting how many patients will enroll for a disease that's still emerging, such as stroke, isn't a thing anybody — if somebody claims they're capable of it, I'd tell you to disregard whatever they project. So that's not something we'll be doing. What we've communicated is that things are going well; we're where we should be, and we feel positive about it; even so, we've also stated that Thunderbolt isn't included anywhere in our 2023 projections when it comes to revenue. So we're not suggesting — and please don't interpret that as things going poorly. They are going well, but we're also staying careful with our forecast such that Thunderbolt is — we'll manage everything and accomplish all the things we committed to doing even with Thunderbolt absent from this year's figures.
Mike Matson
analystI suppose I'll kick things off with the RED catheter; it seemed like perhaps the growth got somewhat better on the neuro side. Could you share your thoughts on how those are performing in Europe? My understanding is that you rolled them out somewhat late in Q3, making this the initial complete quarter they've been available there. Then I had a follow-up regarding RED 43. Could you perhaps explain where that product sits within the lineup and what sets it apart from the remaining catheters?
Adam Elsesser
executiveAbsolutely. I'll work in reverse order. We'll begin with RED 43, after which we'll address the broader question regarding the RED series in Europe, and I can extend that discussion to the U.S. too. RED 43 is still in its early stages, as you're aware, when it comes to launching it and steering it through the different value analysis committees. Yet the procedures that have taken place and the individuals who have performed them have genuinely, genuinely been fond of it; it's an excellent coaxial catheter, and on top of that, having a catheter of that size capable of going distal has been — the response from people has just been really, really positive. We take particular pride in the design efforts that went into that catheter, and I believe there's an obvious need for it in the market. Regarding the broader franchise that RED has established, in both Europe and the U.S., the launch has been excellent; we truly began seeing it in Q4 of 2021. We experienced a surge from that, which in fact has hurt us somewhat on the comparison at present since it was such a strong launch; nevertheless, it has kept going very powerfully and gaining share; so even within a market that currently isn't expanding, that franchise has kept performing well because an increasing number of people are adopting it, and that's precisely what you hope for. You want a product so good that word spreads, people give it a try, and they remain loyal, and that's exactly what's occurring with the RED series; and clearly, that matters enormously for Thunderbolt's success since those catheters are used alongside Thunderbolt. So if those catheters are receiving the kind of response they are, they're trackable, they're the catheters people wish to use, then naturally, progressing and incorporating Thunderbolt into the mix becomes far simpler.
Mike Matson
analystAlright; and regarding the Thunder trial, I might have brought this up during an earlier call, though honestly I can't recall, but is that data going to come out prior to your FDA submission, following it, or at some stage before the product actually reaches the market?
Adam Elsesser
executiveThat's difficult to say. It's going to hinge on when that data becomes available. Should it be ready and there's a major meeting where it could be presented before being disclosed elsewhere, then certainly, you'd get to see it. If the timing on that doesn't line up, we're clearly not going to hold off on submitting to the FDA just so we can present it at the meeting; so it truly comes down to timing, and right now, that's tough to forecast.
Shagun Singh Chadha
analystAs we look ahead to 2023, regarding my questions, I was hoping you might say more about any obvious clinical benefits of Flash in earlier-stage cases, perhaps related to how quickly clots are removed. You brought up speed, efficacy, and safety. Is there a way to put numbers to that? Also, are you noticing more adoption in PE or DVT cases? Then for my second question, I was hoping for a brief update on clinical trial work. On Thunder specifically, I just wanted a sense of how enrollment is going. From what I gather, treatment has to happen within a set window. Does that hold enrollment back at all? Or is everything on schedule?
Adam Elsesser
executiveOkay. Let me try to keep all of these straight. I attempt to jot them down. I may need a reminder. First, you raised the matter of safety and speed and all of that, and yes is the answer. Every one of those is solid, and Flash possesses all of them. Once more, it's among those uncommon situations—at least in our experience across 20-some-odd years in this space—where a product performs that well and carries the sort of buzz that trails it. So you notice it the moment you use it, and that makes us especially pleased, since once again it speaks to how effectively patients can be treated. The following question was about Flash as well, and I hurried to write it down before we moved to Thunderbolt; so remind me what came next.
Shagun Singh Chadha
analystAlright, so actually this is just a follow-up — if you're able to put a number on it, whether in terms of speed or whatever else, if you can quantify it; and then what I was really asking was whether you're seeing more uptake among PE or DVT cases.
Adam Elsesser
executiveYeah, correct. So how would one quantify that? No two cases are alike. Of course, DVT and PE aren't the same thing. And you could get simple — straightforward P cases alongside tougher ones, and the reverse happens with DVT too. So putting numbers on that is difficult, that's the thing you're after. What we have is the impression. What's actually happening is that the people using it are responding very positively, like, wow, that was amazing. It was so simple, so quick and strong, and it simply got the job done. And so quantifying that is tough. We don't — no trial is being run by us on this right now. So I can't give you any figure that would carry any kind of validity. It isn't like some sort of gathering of self-reported data. So I think it simply — it's clearly performing better than what they're accustomed to. So that's the situation. When it comes to DVT and PE, I think what we're seeing is a genuine mix. I think, among the people using it — I mean many of them use it in both. Physicians are responding just as well or just as favorably in each of those. There isn't any clear-cut distinction like, oh, well, I like it, but only for this and not that. If you're responding to it and again, the overwhelming, overwhelming majority of those using it are, it's for DVT and PE both; on the Thunderbolt question, extremely difficult, as I've mentioned a few times, to give you a number for enrollment, stroke enrollment. And I've been part of lots and lots of stroke trials over the years. It comes in fits and starts. You could go 4 days with no case, and then 5 cases will show up in 2 days, that sort of thing; that's how a stroke trial goes; that's no different in the stroke trial, but as I've mentioned, it's — we're in good shape, on track. And again, cautiously, we've made certain that we are counting on this product, for which we don't control the trial's timing, for any revenue in 2023; so from that angle, I think everyone can rest assured that we're in pretty good shape and not out on a limb on that topic.
Samantha Kurtz
analystThis is Sam, filling in for Matt. First off, I wanted to ask whether you could share additional details or some color regarding surgeon training for Lightning Flash, along with whatever feedback physicians have given you on that front.
Adam Elsesser
executiveCertainly. Whether we're talking about surgeon training or interventional training, depending on which specialty it is — physician training — the situation differs somewhat, based on whether that doctor has previously worked with one of our Lightnings. When they have, the setup process looks quite comparable. When they haven't, all we need is to run an in-service and make sure their lab is properly prepared. That said, we've been handling this for quite some time now. As a result, it tends to be fairly uncomplicated. The sole meaningful distinction for those who've worked with Lightning either 7 or 12, or as compared with Lightning Flash, comes down to this: the algorithm works differently, and so does the feedback. On top of that, it packs considerably more power. So training basically involves helping them understand how to approach that, how to interpret it, and what the visual cues on the lights and the audio signals mean. Once again, this isn't unlike anything we've previously done, and it definitely doesn't create any kind of obstacle to adoption — our field team can handle it quite easily.
Samantha Kurtz
analystGreat. And I suppose, as a last quick item on that subject: could you possibly share with us what portion had experience with Lightning before, and what portion hadn't?
Adam Elsesser
executiveThat figure is genuinely difficult to pin down. Tracking it certainly isn't something we do. What I can say is that a good many of our existing accounts have expressed a desire to make the change. Naturally, nobody should find that shocking. The truly encouraging part, though, has been watching people who spent ages saying "I require a larger catheter" now react so strongly, so positively to Flash. As all of us understand, the thing they were after was a system with considerably more power than Lightning 12 might have delivered, and at this point that's what they've got; and so — for those who were never our users before, the way they've responded has been genuinely uplifting, showing that we created and delivered exactly the product everybody was after. Whatever people kept requesting, we've genuinely provided, and that's essentially the job we're meant to do. So that has us feeling quite enthusiastic.
Lei Huang
analystLei here, filling in for Larry Biegelsen. Are you able to hear me?
Adam Elsesser
executiveYes.
Lei Huang
analystLet's return to the topic of gross margin. You mentioned that gross margin would expand by 100 to 200 basis points in this year, and it seems the bulk of that will arrive during the second half. Could you provide a bit more detail about what improves from the first half to the second half to produce that margin expansion? Also, along those lines, could you discuss your thinking on China DVT and how it factors into that outlook? Then I have one more question.
Maggie Yuen
executiveOkay. Yes. Well, thank you for asking. There are two elements at play. As we keep raising thrombectomy volume as a share relative to embolization, you will observe a continuing product mix effect on our gross margin; that is one reason the second half will be stronger than the first half; and additionally, during the first half our operation team is primarily focused on driving demand for these new product launches, so what they prioritize right now is not reaching an optimal level of yield performance and labor efficiency, and we can keep seeing those improvements carry on into the second half of the year.
Jason Mills
executiveAbsolutely. Lei, I'll handle the China question. From a wider health care standpoint in China, the recovery has made us genuinely, genuinely pleased. In the later portion of 2022 — specifically November and December — a lot of hospitals had either closed or were performing procedures at levels somewhat below their usual output, purely as a consequence of the pandemic. Now, physicians there appear to be coming back strongly, putting in extra hours and doing what they can for their patients, which is quite encouraging. You're aware that we have an extremely robust alliance with Genesis, and from a long-term view, we're still in the very early days of it. So our feelings about China overall are positive, and that includes what our forecast assumes regarding the volume-based pricing you brought up.
Lei Huang
analystUnderstood. Then for my next question, taking a wider view. Over the years, Penumbra has built a reputation for refining technology and rolling out iterations. When you consider this new AI-orchestrated technology of yours, in what ways does that shift how you'll handle device iteration moving forward, along with your competitive moat?
Adam Elsesser
executiveWell, that question breaks into a couple of pieces. First, does it alter how we innovate or what we're capable of doing? The response is no, it doesn't. This is something we'll keep pushing on. What we've got right now with Flash is incredible. Is there room to improve it? I can't say. With only 1.5 months of cases, we lack enough data to pinpoint where gains exist beyond what's already clear, and that clarity works in our favor. Still, I'm confident there will be areas we can keep fine-tuning. That's something we'll always pursue. And across the years, our R&D team has shown they excel at exactly that. What I mentioned on the call, and I genuinely believe it, is that we can now, for the very first time, envision a point where removing clot becomes truly routine. We haven't reached it, but it's visible; and innovation will carry us from here to there, a far quicker trip than the one that required all these years to arrive at today; and that's deeply encouraging, given how long we've worked at this. As for the competitive moat, I dislike framing our products that way, since our obvious focus is innovation and patients. Other companies and their actions aren't the point. That said, we clearly hold IP covering this entire mechanism and how it functions. And we clearly anticipate that others will respect that IP, and should they not, we'll discuss it. We're not — that's a kind of dynamic unlike anything we've faced previously, where copying and imitation were possible, yet I doubt it will diminish our push to get these products perfectly dialed in. Even so, it's — like I said, it's the start of a wonderful new chapter. It's exciting.
Bill Plovanic
analystMy first question concerns the Lightning Flash rollout. Could you help us grasp the point at which you shifted from LMR into a full market launch? Once that full launch begins, do you begin with your existing customers, or do you cast a wider net? Also, how should we view the ramp over time? Then, regarding the VAC process, what timeframe is involved in navigating the VAC at hospitals nowadays, to the point where you're actually getting them to trial it — how long does that take before it's on shelves and in everyday use?
Adam Elsesser
executiveYes. I'll attempt to address each of those. First, our evaluation phase moved along fairly fast because of how well this product performed. At the big conference in early January, we said we had already completed it. So we've now been in launch mode for roughly a month plus a couple of weeks. With that said, how does it look? No two launches are alike. Different organizations handle things differently. For this launch, we're essentially working through the entire ordering process. Whoever wants it is beginning the purchasing process at their hospital. Certain ones move very fast, and we can fulfill some orders because, for whatever reason, the hospital desired it or the physician can force it through in a week or 2 or 3. Others take far longer, and a few may require several months to work through. So the range is wide. What's taking place right now is that we're simply moving through that process. And again, anyone who wants it is beginning that process with us; some get satisfied quite quickly while others need more time. We aren't — we can't truly put a number on that, clearly, but it goes without saying that's what the team is doing, besides obviously being present for their first cases and getting everyone reacquainted with the algorithms for this specific product. So once more, we're in really good shape. As I mentioned, this has been among the most thrilling periods I've ever experienced, and it will be our most successful launch. I say that with LIGHTNING BOLT following directly behind it. So I hope to say it again before long, but it's a lot of fun; so thanks for the question, Bill.
Bill Plovanic
analystSo once you go live, will the first ones to get it be the folks you already serve, or...
Adam Elsesser
executiveYeah. No, we treat everyone the same. Any customer is welcome. What I've mentioned before — and this is honestly a pretty distinctive thing about the situation — is that organizations that generally don't deploy Lightning on any big scale are coming to us wanting to adopt it and purchase it. And sure, they've got to work through the steps and deal with value analysis committees and all of that; but the sheer amount of conversation and curiosity surrounding this is what's made it much more enjoyable, clearly; so it all comes down to moving through the steps and handling everything properly, making sure we comply with every hospital's policies and bring them on board the correct way.
Bill Plovanic
analystThen, if I may, regarding LIGHTNING BOLT — you're currently in LMR or the eval stage. My understanding from the comments was that a full market launch would begin after March ends. Since you've already gotten Flash, which uses similar technology, through the process, does that let you speed up the VAC and ordering steps? Or do you still have to go through the same sequence once it reaches full market?
Adam Elsesser
executiveYes. Actually, that's a really great question. I don't believe there's any bonus, so to speak, for saying, "Hey, we'd like to do this again now. Thanks for all that effort, and now we want to repeat it." I don't think that does us any favors. Obviously, I do think that after that launch occurs, there will be a chance to potentially combine them, but we won't see that until the April timeframe and beyond. So for the coming month, as I've mentioned, it's really still going to be Flash, and we'll sort of ensure LIGHTNING BOLT gets through the early cases and all of that. But yes, once we're in the second quarter, I think combining these as a single process through the value analysis committee could make things more efficient.
Jee Hamlyn-Harris
executiveAppreciate it, operator. Our management team and I want to say thanks once more to everyone for being here with us right now and for the attention you're giving Penumbra. We're glad to bring you up to speed during this call covering our first quarter.
Operator
operatorAnd this does conclude today's conference call. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Penumbra, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Penumbra, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Penumbra, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.